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All around tumors 
 
Physiologically, tissue specific cells interact with 
their surrounding stroma to maintain functional-
ity, so that specialized cells can retain a pre-
cisely defined anatomical position, number and 
structural interactions with supportive cells and 
their extracellular matrix [1]. During cancer de-
velopment, transformed cells loose these con-
straints through several types of changes. How-
ever, even in this context, the interplay between 
tumor and stroma seems reciprocal.  
 
Tumor stroma (TS) consists of mesenchymal 
fibroblasts, vascular cells, extracellular matrix 
and immune cells that reside in normal connec-
tive tissue and/or derive from circulating blood 
[2]. Tumor cells (TC) maintain their interactions 
and influence surrounding non-malignant cells 
and, vice versa, the stroma itself can trigger 
tumors [3]. Several findings indicated that tu-
mor progression is promoted by cross-talk be-
tween tumor and his surrounding supporting 
tissue either via cell-to-cell contacts or by se-
creted molecules [4,5].  
 
The main TS-modulating growth factors pro-
duced by TC are represented by fibroblastic 
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Abstract: A tumor represents a complex structure containing malignant cells strictly coupled with a large variety of 
surrounding cells constituting the tumor stroma (TS). In recent years, the importance of TS for cancer initiation, devel-
opment, local invasion and metastases has become increasingly clear allowing the identification of TS as one of the 
possible ways to indirectly target tumors. Inside the heterogeneous stromal cell population, tumor associated fibro-
blasts (TAF) play a crucial role providing both functional and supportive environments. During both tumor and stroma 
development, several findings suggest that TAF could be recruited from different sources such as locally derived host 
fibroblasts, via epithelial/endothelial mesenchymal transitions or from circulating pools of fibroblasts deriving form 
mesenchymal progenitors, namely mesenchymal stem/stromal cells (MSC). These insights prompted scientists to 
identify multimodal approaches to target TS by biomolecules, monoclonal antibodies, and more recently via cell 
based strategies. These latter strategies appear extremely promising, although still associated with debated and un-
clear findings. This review discusses crosstalk between cancers and their stroma, dissecting specific tumor types, 
such as sarcoma, pancreatic and breast carcinoma, where stroma plays distinct paradigmatic roles. The recognition 
of these distinct stromal functions may help in planning effective and safer approaches aimed either to eradicate or 
to substitute TS by novel compounds and/or MSC having specific killing activities. 
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growth factor (bFGF), vascular endothelial 
growth factor (VEGF), platelet-derived growth 
factor (PDGF), epidermal growth factor receptor 
(EGFR)-ligand and transforming growth factor β 
(TGF-β) [4]. All these cytokines are able to alter 
the normal tissue homeostasis stimulating the 
formation of new blood vessels as well as re-
cruiting and activating immune cells and stro-
mal fibroblasts [6-8]. Inside the tumor burden, 
fibroblasts may constitute a substantial volume 
so that in pancreatic and breast cancer (BC), 
they could account for up to 70% of the TS com-
partment playing a pivotal role in tumor mainte-
nance, diffusion and, even drug resistance [9]. 
Based on their presence and trophic functions 
in a variety of tumors, these cells have also 
been referred as tumor associated fibroblasts 
(TAF) [10-12].  
 
The real origin of TAF and the mechanisms by 
which they promote tumor progression is still 
debated, however there are reports demonstrat-
ing that, inside tumor burden, fibroblasts ac-
quire an activated phenotype quite similar to 
one shown during wound repair in injured sites. 
This sort of shift from normal fibroblasts to acti-
vated TAF is driven to a great extent by cancer-
derived cytokines, such as TGF-β [10].  
 
Once transformed, activated fibroblasts present 
several peculiar features. TAF express smooth 
muscle cell markers desmin, α-smooth-muscle-
actin (α-SMA), fibroblast activation protein (FAP) 
and vimentin [13-15]. TAF additionally represent 
the major producer of extracellular matrix 
(ECM), synthesizing type I, type III and type V 
collagen and fibronectin. This generatesa large 
net of fibrillar matrix inside the tumor that em-
beds TC like a supporting scaffold [16]. The high 
number of fibroblasts and their synthesized 
ECM components residing inside the reactive 
stroma gives rise to a pathological condition 
known as desmoplasia characterized by in-
creased amount of collagen, fibronectin, pro-
teoglycans, tenascin C and vessels. Beside this 
supporting action, TAF are also representing an 
important source of ECM-degrading proteases 
such as metalloproteinases that are fundamen-
tal to regulate the motility and invasiveness of 
cancer cells [14]. 
 
In addition to the mentioned mechanisms by 
which TS promotes cancer progression by stimu-
lating proliferation, migration and invasion, 
there is also increasing evidences that TAF gen-
erally favour the initiation of neoplastic events 
from a transition of non-tumorigenic cells to-
wards tumorigenic clones (Table 1) [17, 18]. 
This effect seems strictly related to changes in 
gene expression which may alter the physiologi-
cal function of fibroblasts inducing an abnormal 
phenotype often combined with an overexpres-
sion of cytokines, such as TGF-β and hepatocyte 
growth factor (HGF) [19, 20]. Although non-
Table 1. Tumor associated fibroblasts influ-
ence on tumor progression 
Tumor Source Impact References 
prostate 
carcinoma  
Olumi AF et al. 
Cancer Res. 1999 
1;:5002-11 
breast 
cancer  
Chiavarina B  et al. 
Gene Ther. 2004 
 11:1155-64. 
breast 
cancer  
Akira Orimo et al. 
Cell 2005 
121:335–348 
breast 
cancer  
Sadlonova A  et al. 
Breast Cancer Res. 
2005 
7:R46-59 
breast 
cancer  
Liao D  et al. 
PLoS One. 2009 
 4:7965 
squamous cell 
oral carcinoma  
Kawashiri S  et al. 
Head Neck. 2009 
31:1346-53 
bone and soft 
tissue tumours  
Dohi O  et al. 
Histopathology. 2009 
55: 432-40 
pancreatic ade-
nocarcinoma  
Hwang RF  et al. 
Cancer Res. 2008 
68 ::918-26 
several solid 
tumors  
Francia G  et al. 
Cancer Cell. 2009 
 15:3-5 
breast 
cancer  
Spaeth EL et al. 
PLoS One. 2009 
4:4992 
pancreatic 
adenocarci-
noma 
 
Spaeth EL et al. 
PLoS One. 2009 
4:4992 
ovarian adeno-
carcinoma  
Spaeth EL et al. 
PLoS One. 2009 
4:4992 
melanoma  
Balsamo M et al. 
Proc Natl Acad Sci U S 
A. 2009  8::20847-52 
squamous skin 
carcinoma  
Erez N et al. 
Cancer Cell. 2010 
 17:135-47 
Inhibition (), growth () 
  
 
 Mesenkillers for cancer therapy 
 
 
789                                                                                                            Am J Cancer Res 2011;1(6):787-805 
tumorigenic fibroblast may play a role enhanc-
ing proliferation of already malignant epithelial 
cells, they seem unable to initiate the malignant 
transformation of epithelial cells de novo [21]. 
On the contrary, TAF can induce neoplastic 
transformation in normal cells. Olumi et al. de-
scribed that the co-culture of TAF with human 
prostatic epithelial cells resulted in a tumori-
genic epithelial cell phenotype that may even 
persist in the absence of TAF [22]. To further 
underline the involvement of stromal TAF in can-
cerogenesis, several investigators demon-
strated that cancer might also arise as conse-
quence of inherited or acquired genetic muta-
tions in stromal compartment [3,23]. Moreover, 
in patients with juvenile polyposis, deletions of 
chromosome 10 and 18 have been detected in 
stromal cells [24]. Moinfar et al. discovered ge-
netic alteration and loss of heterozygosity in 
stromal cells close to primary BC [25], and very 
interestingly, different scientists reported a tu-
mor like phenotype in fibroblasts obtained from 
healthy relatives of patients with familiar breast 
disease [26, 27].  
 
Tumor stroma ontogeny: resident transdifferen-
tiating cells, circulating mesenchymal progeni-
tors or both? 
 
While large amounts of data are confirming the 
possible roles played by TAF in cancer initiation 
and progression, their ontogeny remains contro-
versial (Figure 1). It has been shown that differ-
ent tumor types may have specific TAF based on 
histology, organ localization and phase of tumor 
development (i.e. tumor initiating phase versus 
metastasis) [13]. Originally, resident normal 
stromal fibroblasts were considered to be the 
major source of TAF, nevertheless more recently 
several independent studies indicate a multi-
Figure 1. The origin of TAF. Tumor associated fibroblasts (TAF) may originate from different sources either by circulat-
ing mesenchymal progenitors derived from bone marrow (BM-MSC), adipose tissue (AD-MSC) or from locally recruited 
fibroblasts. In this latter case, TAF may derive from host normal mesenchymal fibroblasts and from cellular elements 
deriving form epithelial cells resulting from an epithelial-mesenchymal transition (EMT). Alternatively, TAF may be the 
result of another transition in which endothelial cells are the precursors: the endothelial mesenchymal transition 
(EndMT). 
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plicity of cell sources from which TAF may origi-
nate [28]. Accordingly to these data, TAF may 
also derive from transdifferentiating cells within 
the tumor. For instance TAF may be generated 
via an epithelial to mesenchymal transition 
(EMT) or from an endothelial to mesenchymal 
transition (EndMT) [29].  
 
EMT is a complex cellular transformation that 
has been associated with molecular changes 
inducing an epithelial cell depolarization and 
the adoption of a mesenchymal phenotype char-
acterized by an enhanced migratory ability and 
increased expression of extracellular matrix 
protein [30]. EMT is suggested to correlate with 
the malignant phenotype in epithelial derived 
tumors and in sarcomas suggesting that cells 
arising from EMT may be mediating the transi-
tion towards a metastastatic phenotype 
[31,32].  
 
EndMT was first investigated in a case of tissue 
fibrosis but it has also been  demonstrated to 
contribute up to 40% of TAF [33]. EndMT is of-
ten categorised as a specialised form of EMT, 
where endothelial cells represent the starting 
cell population. The molecular mechanisms of 
EndMT in tumors are not yet fully understood 
but is has been suggested to be mediated by 
TGF-β. EndMT may be initiated by autocrine and 
paracrine inflammatory signals originating the 
surrounding tissue. Alternatively, endothelium 
may undergo an indirect EndMT  response to 
vascular injury. Transitioning endothelial cells 
loose their main phenotype and acquire a mi-
gratory phenotype, invade the basal membrane, 
and begin to express mesenchymal markers, as 
reported in other conditions [34]. 
 
Beside these two possible origins of TS genera-
tion by either differentiation or transdifferentia-
tion, several findings indicate that TAF may origi-
nate from a pool of mesenchymal circulating 
cells [35], which could to be either bone-marrow 
(BM) or adipose tissue (AD) derived. The exact 
nature of these progenitors is still under investi-
gation but there are clues that these may be 
sub-populations of mesenchymal stromal/stem 
cells (MSC). MSC are heterogeneous progeni-
tors obtained from different tissues having ro-
bust regenerative potential [36]. While their role 
as regenerative tools has been studied for dec-
ades, only more recently have MSC been associ-
ated with  tumors. 
 
There is much evidences in support of this hy-
pothesis: first human BM-MSC, exposed to tu-
mor-conditioned medium over a prolonged pe-
riod of time, assume a TAF-like myofibroblastic 
phenotype including sustained expression of 
stromal-derived factor-1 (SDF-1) and α-SMA 
[37,38], secondly BM-MSC are able to migrate 
into the tumor burden after systemic or local 
infusion [39-42]. Recently, Hall et al [43] have 
proposed that, during the stromagenesis, local 
tissue fibroblasts as well as circulating MSC 
coming from BM could equally be recruited into 
the tumor burden. They also have supposed 
that, once inside the tumor microenvironment, 
MSC could proliferate and acquire the main 
biological properties of activated TAF. Physio-
logically, BM-MSC play essential roles in main-
taining adult tissues homeostasis as well as in 
wound healing [44]. Accumulating evidence 
demonstrated that, in healthy animals, system-
atically injected MSC, migrated preferentially in 
lung, liver and bone while they were found to a 
smaller extent in other tissues [45-47]. Most 
interestingly, in pathological conditions, MSC 
showed the tendency to preferentially migrate 
into injured sites irrespectively of the organ, 
probably driven by chemotactic gradients due to 
cytokines and chemokines released from the 
damage sites [48-53]. Once there, MSC take 
part to tissue remodelling providing structural 
support and secrete stimulatory factors for tis-
sue repair [44,54]. Starting from these findings, 
one could assume a similar behaviour when in 
tumors that represent “wounds that never 
heal” [5]. In a tumor xenograft murine model, 
Ishii et al. demonstrated that, 28 days after im-
plantation of pancreatic carcinoma cells, about 
40% of TAF within the tumor burden were de-
rived from BM [55]. More recently, others dem-
onstrated a recruitment and engraftment of 
intravenously derived MSC into tumor sites of 
melanoma, breast, gastric and brain tumor 
xenografts [37-39,56]. 
 
Adipose tissue mesenchymal progenitors may 
also contribute to TS. As for BM-MSC, it has 
been shown that systemically administered AD-
MSC can localize to sites of injury and contrib-
ute to revascularization [57]. Similarly to BM-
MSC, AD-MSC migrate into tumor sites in re-
sponse to discrete signals and become incorpo-
rated into the sites of disease serving as an 
extra TAF reserve [58]. Beside their possible 
role as TAF precursors, it has been proposed 
that AD-MSC become recruited for tumor vascu-
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logenesis, suggesting a dual and more complex 
contribution of AD-MSC: TAF generation and 
neoangiogenesis [60].  
 
Even though much evidence show that MSC 
play a role in TS, extensive comparative analy-
ses between MSC and TAF are lacking and iden-
tify the circulating derived component inside the 
population of TAF is extremely difficult. How-
ever, we originally observed that TAF isolated 
from different tumor histotypes (lung, colon and 
pancreas) share the same spindle shape mor-
phology and similar antigen expression (Figure 
2A-B). These data have been recently supported 
also by Johann et al. who demonstrated that 
tumor stromal cells, isolated from neuroblas-
toma and sarcomas, are positive for the main 
mesenchymal markers 
such as CD90, CD73 ad 
CD105 and lack of hema-
topoietic antigens. In 
addition, they were able 
to differentiate tumor 
stromal cells along the 
osteogenic lineage, sug-
gesting some relevant 
similarities between TAF 
and MSC [60]. Similar 
data were also obtained 
by Zhao et al. who, com-
paring prostate derived 
TAF and BM-MSC, re-
vealed antigens similari-
ties, although associated 
with a different gene ex-
pression profile [61]. 
While the antigen simi-
larities may indicate a 
common origin and being 
used to prospectively 
isolate TAF, more recent 
findings suggests that 
TS, just like it has been 
proposed for MSC [62], 
may exert an immuno-
modulatory function 
against lymphocytes and 
NK reducing their anti-
tumor impact and favour-
ing tumor progression 
[60]. All these data sug-
gest TAF and MSC may 
share some relevant phe-
notypical and functional 
features.  
 
Paradigms of tumor and mesenchymal stroma 
interdependence  
 
During recent years, cross-talk between TC and 
stroma has been increasingly unveiled and we 
can now speculate that mesenchymal stromal 
cells may contribute to all the steps of tumori-
genesis. A relevant amount of data suggests 
that stromal cell may be at the origins of tu-
mors, this is the case of bone and soft tissue 
sarcomas where primitive precursors from dif-
ferent origins may play a fundamental role in 
initiating the neoplastic process. Regarding the 
role of stroma in cancer progression, patholo-
gists recognize that tumors markedly differ from 
each other also in term of stromal composition 
Figure 2. Morphological appearance of TAF from a primary lung cancer. 
Representative experiment of tumor associated fibroblasts (TAF) isolated from a 
patient with lung tumor by collagenase digestion, in vitro cultured and expanded. 
The FACS analyses (Panel A) reveal surprising similarities in TAF immunopheno-
type in comparison with mesenchymal stromal/stem cells (MSC). In addition, in 
vitro observations (Panel B; 100 x original magnification) indicate a spindle shape 
morphology of TAF analogous to MSC.  
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that deals with both the type and amount of 
TAF. In particular, in the so called desmoplastic 
tumors, such as pancreatic adenocarcinoma 
(PA) and some BC sub-types, up to 90% of the 
primary tumor burden may consist of stroma 
which it is also reported to promote tumor pro-
gression [63]. 
 
In addition, stromal cells may play a third funda-
mental role in tumorigenicity and namely metas-
tasis and, in particular, for bone metastasis. BC 
cells are known for over 100 years to have a 
specific tropism for BM and for their stromal 
cells [64]. In this very frequent clinical scenario, 
we see TC going into marrow mesenchymal 
stroma and by this interaction, they can gener-
ate secondary lesions often associated with 
high levels of morbidity and mortality [65]. 
 
Here we are considering three different tumor 
types respectively as possible paradigms of fun-
damental aspects of tumor and stroma interac-
tions to outline how mesenchymal stromal cells 
may determine initiation, proliferation and me-
tastasis: sarcomas, pancreatic and BCs, .  
 
Mesenchymal stromal cells as tumor initiators: 
the sarcomas 
 
Sarcomas are malignancies deriving from mes-
enchymal tissues such as fat, bone, cartilage 
and muscle [66]. The relation between these 
tumors and the normal mesenchymal counter-
part is unique: sarcomas are widely believed to 
develop as a result of genetic mutations in mes-
enchymal progenitor cells, nevertheless the ex-
act cellular origin of most of these tumors re-
mains unknown. A proper example of this is 
represented by Ewing’s sarcoma (ES). The on-
togeny of ES initiating cells is still controversial. 
While originally believed to be fully derived from 
primitive neuroectodermal cells by early neural 
markers expression, such as neuron specific 
enolase, S-100, and neurosecretory granules 
[67-69], some doubts regarding this origin are 
arising. In fact, it has been discovered that the 
typical ES translocation involving the EWS-FLI1 
fusion gene, can itself induce neuroectodermal 
differentiation up-regulating a number of genes 
associated with early neural differentiation 
[70,71]. These findings suggested the possibil-
ity that neuroectodermal characteristics of ES 
might be a direct result of EWS-FLI1 expression 
and not necessarily linked to the cell origin and, 
as an alternative hypothesis, it may be that ES 
may derive from MSC [72]. Since most cases of 
ES arise in bone, it seems plausible that the 
initiating cell could be resident in the bone. In 
addition, MSC themselves can exhibit some 
neuroectodermal features, for examples they 
can spontaneously express neural markers in-
cluding S-100, neurofilament M, NGFR, CD56 
and nestin [73,74]. In addition, MSCs can also 
be induced into different neural lineages [75]. 
The hypothesis of a mesenchymal origin of ES 
has been further strengthened in other experi-
ments. ES cell lines with knockdown of EWS-
FLI1 gene display human MSC features includ-
ing induction of mesenchymal markers CD44, 
CD73 and the typical tri-lineage differentiation 
plasticity displayed by primary MSC [76]. Beside 
ES, there is evidence that other sarcomas may 
be initiated by MSC. That is the case for os-
teosarcoma, which seem to arise from BM-MSC 
like cells. Although with a weaker evidence than 
ES, these data suggest that MSC-like cells are 
capable of differentiation into fat and bone and 
recently, Berman et al. demonstrated that the 
combined loss of Rb and p53 in MSC is suffi-
cient to induce osteosarcoma formation in mice 
[77]. Dealing with AD-MSC, various histologic 
types of liposarcoma have been associated with 
MSC. Matushansky et al. showed that liposarco-
mas have been linked with perturbation of MSC 
adipocytic differentiation suggesting a direct 
relationship between a MSC maturation arrest 
and sarcoma [78]. These authors hypothesized 
that, during differentiation, MSC could encoun-
ter an initial genetic assault that leads to differ-
entiation arrest or altered differentiation poten-
tial and that secondary genetic changes may 
induce tumorigenesis.  
 
Tumor-stroma interactions in local tumor pro-
gression: the pancreatic adenocarcinoma 
 
PA is the most common pancreatic tumor and 
accounts for more than 85% of all malignant 
pancreatic neoplasms [79]. Its desmoplastic 
counterpart, unique among solid tumors, is a 
key feature of PA. This is characterized by a 
dense network of stromal elements considered 
to be originated from pancreatic stellate cells 
(PSC), endothelial cells, nerve cells and immune 
cells [80]. PSC, myofibroblasts-like cells identi-
fied as source of fibrosis in chronic pancreatitis, 
could be considered the normal counterpart of 
TAF in PA. PSC origin is still debated with mes-
enchymal, endodermal and neuroectodermal 
derivations as hypotheses. In vitro, PSC may 
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adopt spindle shape morphology with an acti-
vated phenotype characterized by expression of 
α-SMA and desmin [81]. PSC can produce also 
soluble factors and ECM that seem to stimulate 
proliferation and survival of PA cells by providing 
a physical scaffold and growth factor reservoir 
[3, 82]. TAF in PA have been also indicated to 
be originating from a circulating cell pool, and 
MSC recruitment from BM has been recently 
show to be associated with PA [55,83]. Since 
hypoxia influenced stromal cells as well as pan-
creatic cancer cells, the hypoxic environment is 
reported to play a key role in pancreatic cancer 
progression [84]. In this model, the severe hy-
poxia generated within the tumor resulted in a 
dramatic expression of several growth factors 
such as platelet-derived growth factor (PDGF) 
and vascular endothelial growth factor (VEGF), 
representing pivotal chemotactic and mitogenic 
factors for MSC. Thus, MSC can migrate toward 
tumor blood vessels and promote vasculogene-
sis by an autonomous VEGF production and, 
therefore, further empower the pro-angiogenic 
potential of TC [85]. In PA, the role of TAF within 
the desmoplastic reaction is generally consid-
ered a sign of tumor progression, even if the 
great amount of matrix in PA may be, on the 
contrary, a barrier against tumor cell dissemina-
tion [86].  
 
Tumor-stroma relationship in breast cancer: 
from local progression to metastatization 
 
The interaction between TC and TS has been 
described in BC where TC influence stroma and 
vice-versa [87]. BC is a heterogeneous group of 
cancers originating from mammary glands. With 
different extent, BC is also characterized by a 
desmoplastic reaction, which involves the re-
cruitment of a variety of stromal cells with pro-
tumorigenic activities [88]. BC stroma contains 
increased number of TAF and immune cells as-
sociated with an increased collagen I, fibrin 
deposition and enhanced angiogenesis [3]. TGF-
β, produced by BC, promotes a conversion of 
resident tissue fibroblasts into tumor-promoting 
TAF which, similarly for PA, facilitated tumor 
growth and progression. In turn, it is now recog-
nized that the secretion of high levels of other 
molecules, such as stromal-derived factor-1 
(SDF-1α or CXCL12), by TS can trigger specific 
receptors (i.e CXCR4) on BC cell surface and act 
as pro-tumorigenic factors.  
 
This axis SDF-1α/ CXCR4 is also relevant in the 
interaction of BC cells with marrow MSC. BC 
have the ability to attract marrow derived MSC 
and in turn, BC preferentially metastasize to the 
bone marrow. In both cases, SDF-1α seems to 
be involved [89]. In addition, in animal models, 
MSC exhibit increased avidity to tumor sites 
when directly introduced into the peripheral 
blood [90]. Spaeth et al. investigated the possi-
bility that MSC can be converted into TAF [35]. 
The observation that MSC can express an acti-
vated fibroblast phenotype, when exposed to 
xenograft models of BC, may demonstrate that 
microenvironmental stimuli can drive MSC into 
TAF. Karnoub et al. showed how MSC, mixed 
with BC cells before subcutaneous injection, 
can favour neoplastic cell dissemination by se-
creting the chemokine CCL5, suggesting that 
stromal cells in BC may not only facilitate local 
progression but may also enhance their motility, 
invasion and metastasis [89]. Dealing with BC 
metastasis, MSC have been additionally impli-
cated in the interaction with BC cells inside the 
marrow via direct contacts as well as by se-
creted factors, there MSC, within specific 
niches, promote BC growth and invasion 
through multiple molecular mechanisms [35]. 
 
Tumor stroma as a novel but still controversial 
target for cancer therapy  
 
Targeting tumor stroma by molecules as adju-
vant treatment for cancer therapy 
 
Thanks to these multiple evidences underlining 
the central role of TS in cancer formation and 
progression, it is reasonable to assume that a 
damage to TS may led to retardation or abroga-
tion in tumor growth. Presumed advantages in 
targeting TS include that these cells are not as 
genetically unstable as cancer cells and are less 
likely to develop drug resistance. Inside the en-
tire TS compartment, in this review we mostly 
focus on approaches targeting TAF, since these 
elements lead and influence more than others 
cell tumorigenesis [10]. The role of TAF in angio-
genesis, TC proliferation and invasion thanks to 
the release of factors interfering with cell cycle, 
anti-cancer therapies and prevention of immune
-surveillance has been discussed previously
[91,92]. 
 
The cell surface molecule known as fibroblast 
activation protein (FAP) represents a promising 
candidate to specifically  target TAF safely [15]. 
Mature somatic tissues, except for activated 
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fibroblasts during wound healing and within 
tumor stroma, do not express FAP [93]. A phase 
I study, using an anti-FAP antibody in patients 
with advanced colorectal carcinoma or non-
small-lung carcinoma, showed high specificity 
for tumor sites without evident side effects [94].  
 
Several other growth factors and hormones 
have also been  used to decrease the number 
of activated fibroblast in cancer [95-97]. The 
hepatocyte growth factor (HGF)/Met pathway 
has been a target in several early pre-clinical 
studies targeting TAF, since it represents an 
essential molecule in epithelial-stromal 
crosstalk. HGF is primarily expressed by fibro-
blasts, while the cognate receptor, c-Met is ex-
pressed by epithelial cells [98]. Several reports 
have supported the transforming ability of HGF 
[99]. Ohuchida, by irradiating TS cells produced 
an activation of c-Met in carcinoma cells caus-
ing tumor progression. Interestingly, a specific 
antagonistic effect of HGF could block the en-
hanced invasiveness of pancreatic carcinoma 
due to irradiated stroma. More recent data re-
ported the development of a soluble decoy c-
Met receptor that interfered with HGF binding to 
c-Met significantly inhibiting the proliferation 
and metastasis in xenografts [100]. In addition, 
several studies using a competitive agonist of 
Met and anti-HGF-antibody obtained a remark-
able decrease of metastatic potential and TC 
growth [101,102].  
 
TAF also express various types of MMP that play 
a role in both epithelial-TAF signalling and in 
extracellular matrix remodelling. Increased ex-
pression of several MMPs (MMP-9, -2 and -3) or 
decreased expression of their inhibitors (i.e. 
TIMP2) has been associated with tumor pro-
gression or an invasive phenotype [103,104]. 
Recently, early clinical trials based on MMP in-
hibitors were performed to validate this ap-
proach on a large variety of tumor types [105]. 
However, their efficacy has been limited due to 
adverse effects, possibly due to an MMP role in 
normal tissue homeostasis, wound healing and 
angiogenesis [106].  
 
As already mentioned for BC, the SDF1-α/
CXCL2-CXCR4 pathway represents one of the 
possible targets against TS development. The 
CXCR4 antagonist, AMD3100 has been shown 
to be associated with tumor growth inhibitory 
effects in pre-clinical studies, blocking the TS-TC 
interactions within the tumor sites and in paral-
lel reducing the intra-tumoral recruitment of 
marrow derived MSC [107,108].  
 
Recently, Crawford et al. suggested that TAF 
may also mediate a resistance to anti-
angiogenic therapies [91]. In a murine model, 
TAF extracted from an anti-VEGF treatment re-
fractory lymphoma up-regulate PDGF-C mRNA 
levels of up to 200 fold compared to TAF iso-
lated from non-refractory tumors. Those authors 
demonstrated that elevated levels of PDGF-C 
could inhibit the effect of VEGF inhibitors indi-
cating that the use of anti-PDGF-C neutralizing 
antibody may overcome the ineffectiveness of 
the anti-VEGF compounds. In addition, in sensi-
tive tumors, a combinatory treatment with anti-
PDGF-C and anti-VEGF antibodies was revealed 
to be more effective than an anti-VEGF treat-
ment alone. 
 
Since pancreatic cancer represents a tumor 
with a robust desmoplastic reaction, several 
attempts have been established to target TAF.  
COX-2 is a key mediator of inflammation and 
recently this molecule has been shown to be 
expressed both by stromal and tumor epithelial 
cells [109]. Sato at al demonstrated that, in 
primary TAF from pancreatic cancer, COX-2 ex-
pression was markedly increased when TAF 
were co-cultured with cancer cells [110]. Addi-
tionally, it has been also suggested that COX-2 
might promote tumor growth and invasiveness 
[111]. Thus, in this scenario, COX-2 inhibition 
could represent a suitable strategy to prevent 
cancer progression or invasion. 
 
The inhibition of TS proliferation may also allow 
an additional indirect positive impact in oncol-
ogy and in particular it can be associated with 
an improved delivery of cytotoxic agents to TC. 
Olive et al., using a specific inhibitor (IPI-926) of 
Hedgehog receptor expressed on TS and in-
volved in pancreatic cancer desmoplastic reac-
tion [112], were able to inhibit stromal prolifera-
tion and transiently increase tumor vasculariza-
tion. This was followed by an increase delivery 
of gemcitabine to TC and, most importantly, by 
an increased mouse survival. This study also 
demonstrated that inhibition of the Hedgehog 
pathway can reduce tumor-associated stromal 
proliferation confirming a previous study by 
Yauch et al. who have shown that the effective-
ness of HhAntag, an antagonist for Hedgehog 
pathway, was due to its ability to inhibit TS pro-
liferation and this in turn led to inhibition of tu-
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mor growth [113].  
 
Altogether, these results indicate that, although 
TS may not necessarily be the primary target for 
defeating cancer, it can certainly be seen as an 
obstacle to be overcome to profoundly enhance 
anti-tumor effects in drug combinatory ap-
proaches.  
 
Targeting tumor stroma by stromal cells: Trojan 
horses or food for tumors? 
 
An alternative strategy to target TS is suggested 
by one of the possible TAF ontogenies: the circu-
lating MSC pool. Accordingly to this approach, 
based on the powerful capacity of the tumor 
environment to recruit stromal progenitors, one 
can inject high doses of selected and purified 
MSC populations in the attempt to provide killer 
MSC rather than nourish TS progenitors. al-
though this concept has been developed for 
years in our group and in several others, the 
results seem to be contradictory with without an 
unequivocal influence of wild-type MSC against 
tumors (Table 2).  
 
Zipori et al. initially demonstrated a bi-modal 
action of both murine and human BM-MSC 
against several tumor cell lines, describing that 
in vitro MSC caused a dramatic increase in hu-
man lung and colon carcinoma cell lines growth. 
In contrast, MSC inhibited the in vitro cloning of 
both human and murine sarcoma cell lines. 
Thus, these opposite effects seem to depend on 
the tumor type [114]. 
 
In an elegant experimental model of Kaposi 
Sarcoma (KS), the authors have observed that 
intravenous injection of MSC potently inhibited 
tumor growth [115]. The inhibition was ob-
served not only when MSC and KS cells were co-
injected, but also when MSC were administered 
in mice bearing already established tumors. The 
in vivo tumor-suppressive effect of MSC against 
KS was found to be E-cadherin dependent and 
due to a yet unclear inhibition of Akt activation 
within TC. Confirming the pioneering data of 
Zipori, these in vivo data seem to be strictly tu-
mor related, and inhibition was not reproduced 
for other TC types such as breast and prostate 
cancers tested.  
 
Djouad and colleagues described an in vitro 
immunosuppressive effect of both mouse and 
human MSC on activated T lymphocytes, al-
logenic splenocytes and professional antigen 
presenting cells [116]. These findings were 
transferred into an immunocompetent mouse 
model of melanoma co-injected with MSC. In 
those experiments, MSC revealed the capacity 
to facilitate growth and progression of an al-
logenic melanoma cell line, suggesting how 
MSC can facilitate tumor escape from an alloge-
neic immune system.  
 
In a different setting, Karnoub and colleagues 
suggested a critical role of MSC in the develop-
ment of BC metastases. Distinct human BC cell 
lines showed an increased metastatic potential 
to the lungs when subcutaneously co-injected 
Table 2. Bone marrow or adipose derived (BM, 
AD) mesenchymal stromal/stem cells influ-
ence on different tumor types 
Tumor Source Impact References 
melanoma 
cells  
Djouad F.  et al. 
Blood. 2003; 
102: 3837-44 
colon 
carcinoma  
Ohlsson L.  et al. 
Exp Mol Pathol. 2003; 
75 :  248-55 
pancreatic 
adenocarcinoma  
Ishii G. et al. 
Biochem Biophys Res 
Commun. 2003; 
309 : 232-40 
breast 
cancer  
Robinson S.C. et al. 
Cancer Res. 2003; 
63 : 8360-65 
colon 
carcinoma  
Zhu W. et al. 
Exp Mol Pathol. 2006; 
80 :267-74 
Kaposi’s 
sarcoma  
Khakoo A.Y. et al. 
Journ Exp Med. 2006; 
203 :1235-47 
breast 
cancer  
Karnoub A.E. et al. 
Nature 2007; 
449 : 557-65 
breast 
cancer  
Mishra P.J. et al. 
Cancer Res. 2008 ; 
68 : 4331-39 
pancreatic 
adenocarcinoma  
Cousin B. et al. 
Plos ONE 2009; 
4: 1-10 
ovarian 
cancer  
Spaeth E.L. et al. 
Plos ONE 2009; 
4: 1-11 
Kaposi’s sar-
coma, breast, 
lung , prostatic 
cancer 
 
Zhang Y. et al. 
Cancer Res. 2009; 
69: 5259-66 
melanoma 
glioblastoma 
  
 
Kucerova  L. et al. 
Mol Cancer 2010; 
28: 129 
Inhibition (), growth () 
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with MSC.  However, only one cell line showed 
accelerated primary tumor growth when co-
injected with MSCs. Interestingly, the co-
injection of TC with other types of mesenchymal 
cells, such as BJ fibroblasts, did not enhance 
tumor growth or metastasis. In search for fac-
tors differentially expressed in co-cultures of 
human BC cells and MSC, the same authors 
identified the chemokine CCL5-RANTES to be up
-regulated up to 60-fold in co-cultures compared 
to monocultures. It seems that CCL5, released 
from MSC stimulated by TC, induces the recruit-
ment of tumor-associated macrophages and 
endothelial cells in site of primary tumor growth 
enhancing cancer metastatization [117,118]. 
 
In addition, a toll-like receptor ligands known as 
LL-37 has been recently linked to MSC tumor 
homing. Several studies have uncovered how 
different tumor types, including ovarian, breast 
and lung cancer, show a high expression of LL-
37 [119-121]. It has been demonstrated that LL
-37 acts as proliferative signal, pro-angiogeneic 
factor and chemoattractant for various immune 
cells through activation of Formyl Peptide Re-
ceptor Like-1 (FPRL-1) as member of the toll like 
receptor family [122-124]. Coffelt et al. pro-
posed that LL-37, expressed on ovarian cancer 
cells, could be also involved in MSC recruitment 
at tumor site [125], demonstrating LL-37 acti-
vates MSC migration in a dose dependent man-
ner. Their in vivo studies have also shown a 
clear homing of MSCs into tumors demonstrat-
ing that an inhibition of MSC engraftment into 
TC resulted in disorganization of the fibroblast-
vascular network as well as a reduction of tu-
mor growth.  
 
Beside the BM-MSC, AD-MSC have been also 
described to facilitate tumor progression after 
migration from subcutaneous injection into TS 
compartment promoting cancer cells prolifera-
tion [126]. On contrary, Cousin and colleagues 
shown that AD-MSC are able to strongly reduce 
pancreatic cancer cell viability and proliferation, 
inducing a cancer cell necrosis following G1-
phase arrest. The authors were additionally able 
to reproduce the anti-tumorigenic effect of AD-
MSC in vivo demonstrating a strong and long-
lasting inhibition of tumor growth [127]. 
 
Transferring tumor killing activity to MSC: the 
Mesenkillers 
 
MSC have been shown to preferentially inte-
grate and persist into TS. Despite both their pro- 
and anti-neoplastic attitudes are still under in-
vestigation, this feature prompted their use as 
delivery vehicles for various anti-cancer biologi-
cal agents, in particular for that systemic ad-
ministration is precluded due to their short half-
life and excessive toxicity at the doses required 
for a therapeutic benefit [39]. In addition, the 
persistence of cellular vehicles delivering mole-
cules into poorly accessible body sites, such as 
the brain, may by-pass the limits of systemic 
injections often associated with a limited 
bioavailability in those specific districts.  
 
The application of MSC in the gene therapy set-
tings is supported by their favourable biological 
properties suggesting their application as cellu-
lar vehicles. MSC have a relatively simple isola-
tion methods and limited expression of alloanti-
gens; also they retain the ability to be expanded 
in vitro, to be easily manipulated, to engraft in 
animal models and to express therapeutic pro-
teins when systemically or locally injected 
[35,128]. 
 
There have been various approaches to intro-
duce transgenes into MSC (Table 3). Gene deliv-
eries were performed by retroviral, lentiviral and 
adenoviral vectors with different efficiencies. 
While adenoviral vectors have been associated 
by a transient transgene expression [129], the 
use of both Moloney-based and HIV-based retro-
viral vectors have been more stable and effi-
cient [130,131]. In particular, the capacity of 
transducing non-dividing cells represents one of 
the advantages in lentiviral strategy since a sub-
set of mesenchymal progenitors has been de-
scribed to be quiescent [132]. The manipulation 
of MSC was also performed by modifying agents 
enabling a gene penetration through cell mem-
brane. That is the case of physical (i.e. electro-
poration) and/or chemical (i.e. calcium phos-
phate and polycations) agents, still associated 
with a poor efficiency [133,134]. 
 
Based on these distinct gene modification tech-
niques, MSC have been exploited to deliver 
genes encoding for a variety of biological agents 
impacting tumor growth. Generally, these bio-
logical agents are naturally produced anti-
tumoral molecules that can be more efficiently 
and prominently synthetized by the gene modi-
fied MSC. In particular, molecules derived form 
immune effectors (i.e Natural Killer) and physio-
logically targeting tumors have been consid-
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 Table 3.  Strategies to deliver therapeutic transgenes by vector engineered mesenchymal stromal/stem 
cells (MSC) from different sources 
MSC Source Tumor Source 
  
  Vector 
Therapeutic 
Transgene References 
BM 
(human) 
melanoma 
(human) 
 
Adenoviral INF-β 
Studeny M et al. 
Cancer Res. 2002 
1:3603-8 
BM 
(rat) 
brain 
glioma 
(rat) 
 Adenoviral 
 IL-2 
Nakamura K et al. 
Gene Ther. 2004 
11:1155-64 
BM 
(human) 
breast cancer, hu-
man melanoma 
(human) 
 
Adenoviral INF-β 
Studeny M et al. 
J Natl Cancer Inst. 
2004 3: 593-603 
BM 
(human) 
brain  glioma 
(murine) 
 Adenoviral 
 INF-β 
Nakamizo A et al. 
Cancer Res. 2005 
15:3307-18. 
BM 
(human) 
melanoma 
(murine) 
 
Retroviral IL-12 
Elzaouk L 
Exp Dermatol. 2006 
15:865-74 
BM 
 (mouse) 
colon-26 lung  me-
tastasis (murine) 
 
Adenoviral NK4 
Kanehira M et al 
Cancer Gene Ther. 
2007 14:894-903 
AD 
(human) 
colon  adenocarci-
noma (human) 
 
Retroviral Cytosine deaminase (CD) 
Kucerova L et al. 
Cancer Res. 2007 
1:6304-13 
BM 
(mouse) 
lung 
 (murine) 
 
Adenoviral CX3CL1 
Xin H et al. 
Stem Cells. 2007 
25:1618-26 
UCB 
(human) 
glioma 
(human) 
 
Adenoviral stTRAIL 
Kim SM et al. 
Cancer Res. 2008 
1:9614-23 
BM 
(mouse) 
lung 
(murine) 
 
Adenoviral INF-β 
Ren C et al. 
Gene Therapy 2008 
1-8 
BM 
(human) 
lung 
(human) 
 
Adenoviral TRAIL 
Mohr A et al. 
J Cell Mol Med. 
2008;12:2628-43 
AD 
(human) 
prostate 
(human) 
 
Retroviral Cytosine deaminase (CD) 
Cavarretta IT et al. 
Mol Ther. 2010 
18:223-31 
BM 
(human) brain glioma (murine) 
 
Adenoviral S-TRAIL 
Menon LG et al. 
Stem Cells. 2009 
27:2320-30 
BM 
(human) 
glioma 
(human) 
 
Adenoviral Delta24-RGD 
Yong RL et al. 
Cancer Res. 2009 
1:8932-40 
BM 
(human) 
glioma 
(human)  Lentiviral S-TRAIL 
Sasportas LS et al. 
PNAS. 2009 
Mar 24:4822-7 
AD 
(human) 
cervical 
carcinoma 
(human) 
 
Retroviral TRAIL 
Grisendi G et al. 
Cancer Res. 2010 
May 1:3718-29. 
UCB 
(human) 
glioma 
 (human) 
 
Adenoviral IL-12 
Ryu CH et al. 
Hum Gene Ther. 2011 
Jan 24 
BM 
(human) 
breast - prostate 
cancer- 
(human) 
fibrosarcoma 
(murine) 
 
Lentiviral Timidina Kinase  (TK) 
Song C et al. 
Hum Gene Ther. 2011 
22:439-49 
BM: Bone Marrow, AD: Adipose tissue, UCB: umbilical cord blood. 
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ered, such as Interferons (INF) and death-
ligands (DL). According to this, we are transfer-
ring the killing activity of immune cells to MSC, 
suggesting this approach as a mesenkiller–
based therapy.  
 
Studeny et al. have shown that IFN- toxicity, 
after systemic administration, can be reduced 
by a more targeted delivery of MSC secreting-
IFN-β directly into tumors [39]. By adenoviral 
vector modification, MSC were capable to de-
liver IFN-β both in vitro and in distinct xenograft 
models of breast and melanoma. The impact of 
infused of MSC producing IFN-β overcame the 
effect of human recombinant IFN-β injections 
with a prolonged survival of treated animals.  
 
An additional approach adopted to fight mela-
noma, glioma and breast carcinomas [135] re-
lies on the manipulation of MSC to express a 
pro-drug converting enzyme, such as cytosine 
deaminase, an enzyme that converts 5-
fluorocytosine to a soluble toxic molecule that 
kills both MSC and the neighbouring cancer 
cells through a bystander effect. 
 
The MSC based oncolytic viral therapy, by local 
delivery in brain tumors, constitutes a further 
example. Yong et al showed that a delivery of 
the Δ24-RGD virus, a tumor selective replication 
competent adenovirus with specific cellular in-
fectivity to tumors, produces long term survival 
in an animal model of glioma. This underlines 
how MSC are suitable to delivery Δ24-RGD to 
the brain overcoming multiple barriers of intra-
cerebral viral infection [136,137].  
 
MSC can be also modified to mimic plasma 
cells producing monoclonal antibodies such as 
the scFv EGFRv III, which targets EGF receptor 
on glioma cells surface [138]. These MSC pro-
ducing antibodies represent a paradigmatic 
strategy to more efficiently deliver therapeutic 
molecules that poorly penetrate the blood brain 
barrier acting as efficient therapeutic vehicles 
for malignant brain tumors 
 
Recently, MSC from bone marrow, adipose tis-
sue and umbilical cord have been modified with 
members of the DL family which includes tumor 
necrosis factor (TNF-alpha) and TNF-related 
apoptosis inducing ligands (TRAIL) as powerful 
anti-cancer molecules limited in their systemic 
delivery to patients. At present, although TNF-
alpha variants have been recently produced by 
modified MSC in a prostate cancer model [139], 
TRAIL has a significantly higher therapeutic pro-
file against cancer: TRAIL signalling pathways, 
predominantly triggered by death receptors, 
could induce apoptosis in cancer cells without 
significant toxicity toward normal cells [140]. 
The recombinant TRAIL in vivo administration 
has been limited by short half-life in plasma and 
undesired toxicity against normal tissues [141]. 
For these reasons, several investigators have  
shown that MSC expressing both transmem-
brane and secreted TRAIL are able to infiltrate 
and abrogate tumors. Kim et al described that 
human umbilical cord blood mesenchymal stro-
mal cells (UCB-MSC) are suitable cellular vec-
tors for TRAIL delivery, since these cells were 
resistant to TRAIL-mediated apoptosis revealing 
a marked migratory ability and potent anti-
tumoral activity toward glioma [142]. These 
data were supported by Menon et al using BM- 
MSC modified with a lentivirus expressing secre-
table form of TRAIL (S-TRAIL). That study con-
firmed that BM-MSC expressing S-TRAIL might 
provide a performing drug delivery system for 
intracranial glioma [143]. Other tumor types 
were tested, and Mohr et al. described the use 
of MSC expressing TRAIL against a lung cancer 
cell line. They genetically modified BM-MSC by 
an adenoviral vector expressing the full length 
human TRAIL and induced apoptosis by cell-to-
cell contact both in vitro and in vivo [144]. More 
recently, others reported how murine BM-MSC 
may transport S-TRAIL to induce human pancre-
atic cancer death without the need of cell-to-cell 
contact. With the limitations to a xenogenic ap-
proach, this secretable TRAIL delivery by murine 
MSC could be more efficient to eradicate tu-
mors without the need of cell proximity [145]. 
 
We have recently reported that also adipose AD-
MSC may efficiently transport membrane-bound 
full-length TRAIL [90]. In this context, we 
showed that 3 different tumor cell lines repre-
sentative of cervical carcinoma, pancreatic and 
colon cancer are susceptible to AD-MSC armed 
by TRAIL. More importantly, isolating and co-
culturing primary lung cancer cells with AD-MSC 
armed by TRAIL, we were able to induce apop-
tosis in vitro, suggesting this strategy may be 
actually introduced as a therapeutic option for 
incurable cancers. 
 
We also uncovered that this anti-tumor effect 
was essentially due to a cell to cell contact be-
tween AD-MSC expressing TRAIL and TC, medi-
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ated by caspase-8 activation which rapidly acti-
vated and induce cell death. Our study also in-
vestigated the feasibility of associating the AD-
MSC TRAIL approach with other therapeutic 
agents, such as Bortezomib, a well-known pro-
teasome inhibitor. TRAIL refractory tumors were 
then treated in vitro in the attempt to sensitize 
them to our cell therapy approach. The obtained 
results demonstrated the synergic effect of AD-
MSC TRAIL and Bortezomib against a BC tumor 
cell line, known to be resistant to TRAIL. Finally, 
by two different animal models, we demon-
strated that TRAIL producing AD-MSC were able 
to migrate and persist in tumors without toxic 
effect and with a relevant benefit. These in vivo 
models revealed also more prominent HeLa 
growth in mice treated with AD-MSC only la-
belled with GFP in comparison with TC alone, as 
described for wild-type BM- and AD-MSC [126]. 
Interestingly, this trend decreased over time 
and in the late time points appeared totally re-
versible. The reasons behind this phenomenon 
are currently under investigation; it may be pos-
sible that the ratios between AD-MSC and TC 
can initially be in favour of a proliferative burst, 
however when cancer cells become prevalent, 
the amount of AD-MSC may not be adequate to 
feed TC. Nevertheless, the anti-proliferative ef-
fect exerted by mesenkillers producing TRAIL 
was able not only to counterbalance the tumor 
supportive capacity of AD-MSC, but also deter-
mine a powerful inhibitory effect opening, a 
novel promising approach for targeting cancer. 
 
While the identification of supportive cancer 
stroma is a relatively old concept, the strategy 
to identify stromal cells as therapeutic targets is 
increasingly possible by the understanding of 
the complex interplays between tumor and 
stroma. It may be that, by this strategy, we will 
not be able to cure all the still incurable cancers 
but, certainly, one would be a great start. 
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